Nadir Mahmood, PhD

Nadir Mahmood serves as Chief Financial and Business Officer of Nkarta, a cell therapy company developing engineered natural killer cells for oncology. Prior to Nkarta, he headed corporate development at Second Genome where he was responsible for establishing strategy and partnerships across the company’s portfolio of programs and oversaw all intellectual property matters. Earlier in his career, Dr. Mahmood was Staff Scientist at Kythera Biopharmaceuticals (acquired by Allergan), overseeing preclinical research for the company’s lead molecule, Kybella®. He has also worked in equity research at Goldman Sachs and consulted for early stage companies in the life sciences and clean energy sectors. Nadir has a bachelor’s degree in Biochemistry from the University of Texas at Austin, a doctoral degree from the Department of Pharmacology at UT Southwestern, and completed postdoctoral research at the Scripps Research Institute in La Jolla, CA.